HCV Treatment for Patients with Protease & NS5A Resistance
Reported by Jules Levin
New HCV regimens are in phase 3 or phase 2 which will be useful & effective for patients who were previously treated & with HCV drug resistance to protease and / or NS5A, the 1st link below takes you to tables looking at in vitro activity giving a sense of efficacy for new drugs effectiveness against resistance. And Cocrystal Pharma and Trek are in early stages of developing new HCV drugs that are planned to be active against HCV resistance in protease & NS5A.
